Alx Oncology Holdings (ALXO) EBITDA Margin (2019 - 2020)
Alx Oncology Holdings (ALXO) reported EBITDA Margin of 2046.87% for Q2 2020, down 172339.0% on a YoY basis from N/an in Q3 2019, and down 155.76% sequentially from 800.31% in Q1 2020.
Alx Oncology Holdings (ALXO) EBITDA Margin (2019 - 2020) Analysis & Trends
Alx Oncology Holdings (ALXO) has 2 years of EBITDA Margin data on file, last reported at 2046.87% in Q2 2020.
- For the quarter ending Q2 2020, EBITDA Margin fell 172339.0% year-over-year to 2046.87%; the trailing twelve-month figure through Mar 2021 stood at 9986.53% (down 952946.0% YoY), and the FY2020 full-year result was 3693.99%, down 329401.0% from the prior year.
- EBITDA Margin declined to 2046.87% in Q2 2020, from 800.31% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 241.56% in Q3 2019 to a low of 2046.87% in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -2,046.87% |
| Mar 31, 2020 | -800.31% |
| Dec 31, 2019 | -637.51% |
| Sep 30, 2019 | -241.56% |
| Jun 30, 2019 | -323.47% |